{
    "nct_id": "NCT03118947",
    "title": "A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2020-04-02",
    "description_brief": "To evaluate the safety and tolerability of pimavanserin over 52 weeks of treatment in subjects with probable AD who have symptoms of agitation and aggression",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "Patients from parent study ACP-103-032 who were eligible to participate in this study were consented prior to the final procedures performed for study ACP-103-032 at Week 12. The ACP-103-032 Week 12 visit was also considered the baseline visit of study ACP-103-033. The ACP-103-033 result tables are all based on the safety analysis set (n=78).",
            "recruitmentDetails": "This open-label extension study included patients completing double-blind, randomised, placebo-controlled study ACP-103-032 (NCT02992132).",
            "groups": [
                {
                    "id": "FG000",
                    "title": "All Patients",
                    "description": "All patients started treatment with pimavanserin 20 mg once daily (QD). At the Week 2 visit, the dose could be increased to 34 mg QD based on the investigator's assessment of clinical response. Subsequently, the dose could be adjusted from 34 mg to 20 mg or from 20 mg to 34 mg at any visit based on clinical response."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "78"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "49"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "29"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "7"
                                }
                            ]
                        },
                        {
                            "type": "Death",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Lack of Efficacy",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "4"
                                }
                            ]
                        },
                        {
                            "type": "Non-compliance with study drug",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Protocol Violation",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by caregiver",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                }
                            ]
                        },
                        {
                            "type": "Change in patient's living situation",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "4"
                                }
                            ]
                        },
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "Treated patients (i.e. patients receiving at least 1 dose of open-label study drug)",
            "groups": [
                {
                    "id": "BG000",
                    "title": "All Patients",
                    "description": "All patients started treatment with pimavanserin 20 mg once daily (QD). At the Week 2 visit, the dose could be increased to 34 mg QD based on the investigator's assessment of clinical response. Subsequently, the dose could be adjusted from 34 mg to 20 mg or from 20 mg to 34 mg at any visit based on clinical response."
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "78"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "76.9",
                                            "spread": "7.79"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "37"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "41"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "2"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "69"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Duration of symptoms of Alzheimer's disease",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6.2",
                                            "spread": "2.32"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Treatment Emergent Adverse Events (TEAEs)",
                    "description": "Safety and tolerability of pimavanserin after 52 weeks of treatment in patients with probable Alzheimer's disease who have symptoms of agitation and Aggression, in terms of occurrence of TEAEs",
                    "populationDescription": "Treated patients (i.e. patients receiving at least 1 dose of open-label study drug)",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "All Patients",
                            "description": "All patients started treatment with pimavanserin 20 mg once daily (QD). At the Week 2 visit, the dose could be increased to 34 mg QD based on the investigator's assessment of clinical response. Subsequently, the dose could be adjusted from 34 mg to 20 mg or from 20 mg to 34 mg at any visit based on clinical response."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "78"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "53"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "52 weeks",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "All Patients",
                    "description": "All patients started treatment with pimavanserin 20 mg once daily (QD). At the Week 2 visit, the dose could be increased to 34 mg QD based on the investigator's assessment of clinical response. Subsequently, the dose could be adjusted from 34 mg to 20 mg or from 20 mg to 34 mg at any visit based on clinical response.",
                    "deathsNumAffected": 3,
                    "deathsNumAtRisk": 78,
                    "seriousNumAffected": 12,
                    "seriousNumAtRisk": 78,
                    "otherNumAffected": 20,
                    "otherNumAtRisk": 78
                }
            ],
            "seriousEvents": [
                {
                    "term": "Cerebral haemorrhage",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Dyspepsia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Syncope",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Dementia Alzheimer's type",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Myocardial infarction",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Cholecystitis acute",
                    "organSystem": "Hepatobiliary disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Respiratory failure",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Diverticulitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Escherichia bacteraemia",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Pneumonia",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Pelvic fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Renal failure",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Spondylolisthesis",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 78
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 7,
                            "numAffected": 7,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 9,
                            "numAffected": 6,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Upper respiratory tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 6,
                            "numAffected": 5,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Agitation",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 8,
                            "numAffected": 5,
                            "numAtRisk": 78
                        }
                    ]
                },
                {
                    "term": "Weight decreased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA (19.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 78
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "Investigator may publish the study results, relative to his/her own patients, only after review, comment and approval by the sponsor. No publication of confidential information shall be made without the sponsor's prior written consent. At least 60 days prior to submitting a manuscript or prior to any public presentation, a copy of the manuscript or presentation will be provided to the sponsor for review and comment. The sponsor has 60 days to review and comment."
            },
            "pointOfContact": {
                "title": "Sr. Dir. Medical Information and Medical Communications",
                "organization": "ACADIA Pharmaceuticals Inc.",
                "email": "medicalinformation@acadia-pharm.com",
                "phone": "858-261-2897"
            }
        }
    },
    "target_category": "neuropsychiatric symptom improvement",
    "drug": [
        "Pimavanserin (Nuplazid) \u2014 selective 5\u2011HT2A receptor inverse agonist/antagonist; small\u2011molecule antipsychotic, typically 34 mg oral once daily."
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests pimavanserin for agitation and aggression in probable Alzheimer\u2019s disease (intended effect = treat neuropsychiatric symptoms, not to modify AD pathology or directly improve cognition). Pimavanserin is a selective 5\u2011HT2A receptor inverse agonist/antagonist (small molecule) used to treat psychosis and related neuropsychiatric symptoms. \ue200cite\ue202turn0search2\ue202turn0search5\ue201",
        "Act: Key trial details \u2014 title and registration: \u201cA 52\u2011Week Open\u2011Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease\u201d (ClinicalTrials.gov NCT03118947), an open\u2011label 52\u2011week extension evaluating safety/tolerability in AD patients with agitation/aggression. The open\u2011label extension means no placebo arm in this extension. \ue200cite\ue202turn1search3\ue202turn1search6\ue201",
        "Act (mechanism & prior evidence): Pimavanserin is approved for hallucinations and delusions in Parkinson\u2019s disease psychosis and has been studied for neuropsychiatric symptoms (including agitation/aggression) in dementia and AD; prior randomized and open\u2011label studies have examined its effects on agitation/psychosis in AD. \ue200cite\ue202turn0search6\ue202turn1search1\ue202turn0search1\ue201",
        "Reflect: Classification rationale \u2014 According to the definitions: it is not a biologic nor a disease\u2011modifying treatment directed at amyloid/tau, nor primarily a cognitive enhancer. Its pharmacology and trial aim (reduce agitation/aggression) place it in category 4: neuropsychiatric symptom improvement. The open\u2011label 52\u2011week design tests long\u2011term safety/tolerability for treating these behavioral symptoms rather than disease modification. \ue200cite\ue202turn1search1\ue202turn1search7\ue201",
        "Web search results / sources (selected): ClinicalTrials.gov record for NCT03118947 matching the exact title and 52\u2011week OLE details. \ue200cite\ue202turn1search3\ue201; PubMed / study reports describing pimavanserin as a selective 5\u2011HT2A inverse agonist and open\u2011label / OLE safety data in dementia/AD populations. \ue200cite\ue202turn0search2\ue202turn1search1\ue201; Post\u2011hoc and other analyses showing pimavanserin effects on agitation/aggression in AD populations. \ue200cite\ue202turn0search1\ue201."
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational drug is pimavanserin, a selective serotonin (5-HT2A) receptor inverse agonist/antagonist \u2014 i.e., it acts on a neurotransmitter receptor rather than on amyloid, tau, inflammation, etc. It is being tested to treat agitation/aggression (neuropsychiatric symptoms) in Alzheimer's disease rather than to modify underlying AD pathology. \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Act: Key extracted details \u2014 drug: pimavanserin (Nuplazid), mechanism: selective 5\u2011HT2A inverse agonist/antagonist; trial: 52\u2011week open\u2011label extension evaluating safety/tolerability in AD patients with agitation/aggression (ClinicalTrials.gov entry NCT03118947 / trial registry reports). These facts support classification under CADRO category D: Neurotransmitter Receptors. \ue200cite\ue202turn0search5\ue202turn1search5\ue201",
        "Reflect: The classification was checked against CADRO definitions \u2014 pimavanserin\u2019s primary pharmacology targets a neurotransmitter receptor (serotonin 5\u2011HT2A), so D) Neurotransmitter Receptors is the most specific fit. The trial\u2019s aim (symptom control, safety/tolerability in an open\u2011label extension) confirms this is a neuropsychiatric symptom\u2011directed, receptor\u2011targeted intervention rather than disease modification. If multiple molecular pathways had been targeted or the intervention were non\u2011therapeutic, a different CADRO code (R or T) would be considered; here neither applies. \ue200cite\ue202turn2search5\ue202turn1search2\ue201",
        "Web search results / sources (selected): FDA approval and mechanism summary for Nuplazid (pimavanserin). \ue200cite\ue202turn0search0\ue202turn0search5\ue201; Clinical trial registry / reporting for NCT03118947 (52\u2011week open\u2011label extension in AD agitation/aggression). \ue200cite\ue202turn1search5\ue201; Open\u2011label extension safety publication and summary (long\u2011term safety/tolerability in neurodegenerative disease populations). \ue200cite\ue202turn2search5\ue201; Post\u2011hoc analyses showing pimavanserin effects on agitation/aggression in AD cohorts. \ue200cite\ue202turn1search2\ue201"
    ]
}